Early treatment with fumagillin, an inhibitor of methionine aminopeptidase-2, prevents pulmonary hypertension in monocrotaline-injured rats

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Kass, Daniel J ^a   Rattigan, Eileen ^b   Kahloon, Rehan ^a   Loh, Katrina ^c   Yu, Liyang ^a   Savir, Asaf ^c   Markowski, Mark ^c   Saqi, Anjali ^c   Rajkumar, Revathi ^a   Ahmad, Ferhaan ^a   Champion, Hunter C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b GEISINGER HEALTH SYSTEM   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMAGILLIN; METHIONYL AMINOPEPTIDASE 2; MONOCROTALINE; PLATELET DERIVED GROWTH FACTOR; SMALL INTERFERING RNA; AMINOPEPTIDASE; CYCLOHEXANE DERIVATIVE; GLYCOPROTEIN; METAP2 PROTEIN, RAT; SESQUITERPENE; UNSATURATED FATTY ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EARLY INTERVENTION; ENZYME INHIBITION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART RIGHT VENTRICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; TREATMENT RESPONSE; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HEART VENTRICLE; HEMODYNAMICS; METABOLISM; MYOFIBROBLAST; PATHOLOGY; PATHOPHYSIOLOGY; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT;

ANIMALIA; MUS; RATTUS;

AMINOPEPTIDASES; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CYCLOHEXANES; DISEASE MODELS, ANIMAL; FATTY ACIDS, UNSATURATED; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HEART VENTRICLES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; MYOCYTES, CARDIAC; MYOCYTES, SMOOTH MUSCLE; MYOFIBROBLASTS; PLATELET-DERIVED GROWTH FACTOR; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES;

EID: 84859587920     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035388     Document Type: Article

References (50)

1. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, et al. (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54: S55-66.
2. Halpern SD, Doyle R, Kawut SM, (2008) The ethics of randomized clinical trials in pulmonary arterial hypertension. Proc Am Thorac Soc 5: 631-635.
3. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF, (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297: L1013-1032.
4. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, et al. (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173: 1023-1030.
5. Rubin LJ, (2006) Pulmonary arterial hypertension. Proc Am Thorac Soc 3: 111-115.
6. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S.
7. Budhiraja R, Tuder RM, Hassoun PM, (2004) Endothelial dysfunction in pulmonary hypertension. Circulation 109: 159-165.
8. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, et al. (2008) Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 205: 361-372.
9. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, et al. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821.
10. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, et al. (2006) Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28: 1195-1203.
11. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, et al. (2005) Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25: 244-249.
12. Kass D, Bridges RS, Borczuk A, Greenberg S, (2007) Methionine aminopeptidase-2 as a selective target of myofibroblasts in pulmonary fibrosis. Am J Respir Cell Mol Biol 37: 193-201.
13. Koyama H, Nishizawa Y, Hosoi M, Fukumoto S, Kogawa K, et al. (1996) The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I. Possible involvement of cyclin-dependent kinase 2. Circ Res 79: 757-764.
14. Yeh JR, Mohan R, Crews CM, (2000) The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci U S A 97: 12782-12787.
15. Datta B, (2000) MAPs and POEP of the roads from prokaryotic to eukaryotic kingdoms. Biochimie 82: 95-107.
16. Turk BE, Griffith EC, Wolf S, Biemann K, Chang YH, et al. (1999) Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 6: 823-833.
17. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, et al. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557.
18. Liu S, Widom J, Kemp CW, Crews CM, Clardy J, (1998) Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 282: 1324-1327.
19. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, et al. (1997) The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A 94: 6099-6103.
20. Wang YQ, Ikeda K, Ikebe T, Hirakawa K, Sowa M, et al. (2000) Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats. Hepatology 32: 980-989.
21. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, et al. (2004) TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 66: 1677-1685.
22. Katzenstein HM, Rademaker AW, Senger C, Salwen HR, Nguyen NN, et al. (1999) Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 5: 4273-4278.
23. Ohta Y, Watanabe Y, Tabata T, Oda M, Hayashi Y, et al. (1997) Inhibition of lymph node metastasis by an anti-angiogenic agent, TNP-470. Br J Cancer 75: 512-515.
24. Huang ZH, Fan YF, Xia H, Feng HM, Tang FX, (2003) Effects of TNP-470 on proliferation and apoptosis in human colon cancer xenografts in nude mice. World J Gastroenterol 9: 281-283.
25. Brakenhielm E, Cao R, Gao B, Angelin B, Cannon B, et al. (2004) Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res 94: 1579-1588.
26. Burkhoff D, Mirsky I, Suga H, (2005) Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 289: H501-512.
27. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA, (2008) Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 3: 1422-1434.
28. Zuckerbraun BS, Shiva S, Ifedigbo E, Mathier MA, Mollen KP, et al. (2009) Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation. Circulation 121: 98-109.
29. Bridges RS, Kass D, Loh K, Glackin C, Borczuk AC, et al. (2009) Gene expression profiling of pulmonary fibrosis identifies Twist1 as an antiapoptotic molecular "rectifier" of growth factor signaling. Am J Pathol 175: 2351-2361.
30. Rajkumar R, Konishi K, Richards TJ, Ishizawar DC, Wiechert AC, et al. (2010) Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 298: H1235-1248.
31. Champion HC, Michelakis ED, Hassoun PM, (2009) Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 120: 992-1007.
32. Lappin PB, Roth RA, (1997) Hypertrophy and prolonged DNA synthesis in smooth muscle cells characterize pulmonary arterial wall thickening after monocrotaline pyrrole administration to rats. Toxicol Pathol 25: 372-380.
33. Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO, (2000) Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci U S A 97: 6427-6432.
34. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, et al. (2008) Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 81-88.
35. Balasubramaniam V, Le Cras TD, Ivy DD, Grover TR, Kinsella JP, et al. (2003) Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284: L826-833.
36. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, et al. (1998) Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11: 554-559.
37. Baisch H, Gerdes J, (1990) Identification of proliferating cells by Ki-67 antibody. Methods Cell Biol 33: 217-226.
38. Denton MD, Magee C, Melter M, Dharnidharka VR, Sayegh MH, et al. (2004) TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy. Transplantation 78: 1218-1221.
39. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, et al. (2010) Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 182: 652-660.
40. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, et al. (2009) Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 120: 1951-1960.
41. Faber MJ, Dalinghaus M, Lankhuizen IM, Bezstarosti K, Verhoeven AJ, et al. (2007) Time dependent changes in cytoplasmic proteins of the right ventricle during prolonged pressure overload. J Mol Cell Cardiol 43: 197-209.
42. Faber MJ, Dalinghaus M, Lankhuizen IM, Steendijk P, Hop WC, et al. (2006) Right and left ventricular function after chronic pulmonary artery banding in rats assessed with biventricular pressure-volume loops. Am J Physiol Heart Circ Physiol 291: H1580-1586.
43. Umar S, Iorga A, Matori H, Nadadur RD, Li J, et al. (2011) Estrogen Rescues Pre-existing Severe Pulmonary Hypertension in Rats. Am J Respir Crit Care Med.
44. Zou Y, Li J, Ma H, Jiang H, Yuan J, et al. (2011) Heat shock transcription factor 1 protects heart after pressure overload through promoting myocardial angiogenesis in male mice. J Mol Cell Cardiol 51: 821-829.
45. Warder SE, Tucker LA, McLoughlin SM, Strelitzer TJ, Meuth JL, et al. (2008) Discovery, identification, and characterization of candidate pharmacodynamic markers of methionine aminopeptidase-2 inhibition. J Proteome Res 7: 4807-4820.
46. Griffith EC, Su Z, Turk BE, Chen S, Chang YH, et al. (1997) Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 4: 461-471.
47. Kim S, LaMontagne K, Sabio M, Sharma S, Versace RW, et al. (2004) Depletion of methionine aminopeptidase 2 does not alter cell response to fumagillin or bengamides. Cancer Res 64: 2984-2987.
48. Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, et al. (2002) Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 20: 4440-4447.
49. Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, et al. (1997) A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 3: 1501-1505.
50. Tran HT, Blumenschein GR Jr, Lu C, Meyers CA, Papadimitrakopoulou V, et al. (2004) Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54: 308-314.